Trials / Completed
CompletedNCT00079976
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
A Clinical Research Study to Evaluate the Safety and Efficacy of Tigecycline in the Treatment of Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
Conditions
- Gram-Positive Bacterial Infections
- Staphylococcus Infections
- Vancomycin Resistance
- Methicillin Resistance
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tigecycline |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2004-03-22
- Last updated
- 2013-02-08
Source: ClinicalTrials.gov record NCT00079976. Inclusion in this directory is not an endorsement.